Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

The partnership with Sanofi, which focuses on IgM-based agonists targeting autoimmune and inflammatory diseases, includes three preclinical candidates with potential milestone payments exceeding ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

IGM still has an immunology research partnership with biotech giant Sanofi, but the cuts to imvotamab and the other antibody leave the firm without any other projects in its listed pipeline.

IGM Biosciences (NASDAQ ... efforts and despite milestone payments attributed to a collaboration with Sanofi (SNY). “With no clinical assets, no clarity on strategic alternatives, and continuing ...

who estimates that IGM will likely run out of cash sometime in 2027, even with sharply reduced expenditures and assuming future milestone payments from its early-stage Sanofi (SNY) collaboration.

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to ...